India plans instant licence suspension for drugs failing quality tests

India's health ministry has proposed immediately suspending a company's manufacturing licence for any drug found 'not of standard quality' on assay, dissolution, impurities or sterility tests. The move aims to close the gap between a failed test and regulatory action, during which unsafe drugs may stay in circulation. September's alert listed 330 such medicines.